NCT00921154View on ClinicalTrials.gov

Ivermectin Solution Bioequivalence Study - Fasted

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

May 31, 2005

Study Completion Date

September 30, 2005

Conditions
Healthy
Interventions
DRUG

ivermectin

Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.

Trial Locations (1)

Unknown

Shandon Clinic, Cork

All Listed Sponsors
lead

Johnson & Johnson Consumer and Personal Products Worldwide

INDUSTRY

NCT00921154 - Ivermectin Solution Bioequivalence Study - Fasted | Biotech Hunter | Biotech Hunter